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Introduction: Irritable bowel syndrome (IBS), lymphocytic enteritis (LE) and fibromyalgia syndrome (FMS) are three
common disorders. Since a gluten-free diet (GFD) has been shown to be helpful in LE, we aimed to assess its effect
in a series of LE patients also diagnosed with IBS and FMS.
Methods: The study sample comprised 97 IBS plus FMS adult females, of whom 58 had LE (Marsh stage 1), and 39
had a normal duodenal biopsy (Marsh stage 0). All patients fulfilled the Rome III and American College of
Rheumatology 1990 criteria. All participants followed a GFD, the effectiveness of which was assessed by changes in
the results of several tests, including those of the Fibromyalgia Impact Questionnaire (FIQ), the Health Assessment
Questionnaire (HAQ), tender points (TPs), the Short Form Health Survey (SF-36), and the Visual Analogue Scales
(VAS) for gastrointestinal complaints, pain and fatigue.
Results: At baseline, all patients had a poor quality of life (QoL) and high VAS scores. After one year on a GFD, all
outcome measures were somewhat better in the Marsh stage 1 group, with a mean decrease of 26 to 29% in the
TPs, FIQ, HAQ and VAS scales, accompanied by an increase of 27% in the SF-36 physical and mental component
scores. However, in the IBS plus FMS/Marsh stage 0 group, the GFD had almost no effect.
Conclusions: This pilot study shows that a GFD in the LE-related IBS/FMS subgroup of patients can produce a
slight but significant improvement in all symptoms. Our findings suggest that further studies of this subject
are warranted.Introduction
Irritable bowel syndrome (IBS), fibromyalgia syndrome
(FMS) and lymphocytic enteritis (LE) are three common
disorders that can occur in the same subject. Specifically,
FMS occurs in 20 to 32% of people with IBS [1]. IBS has
been found in 32 to 70% of people with FMS [2,3], and
LE has been found in 16% of people with IBS, and in
56% of people with both IBS and FMS [4,5].
IBS is a functional gastrointestinal disorder, characterised
by the presence of chronic abdominal pain or discomfort,
and changes in the intestinal habit, bloating and abdominal
distension. FMS is a chronic syndrome characterised by* Correspondence: lrodrigosaez@gmail.com
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unless otherwise stated.widespread pain, generalised tender points, fatigue, restless
sleep, and various other symptoms suggestive of central
nervous system dysregulation. Both diseases are preva-
lent chronic central sensitisation disorders respectively
classified according to the Rome III [6] and the 1990
American College of Rheumatology (ACR) criteria [7],
once other typified diseases have been ruled out by ap-
propriate studies.
On the other hand, LE (also known as lymphocytic
duodenosis, or Marsh stage 1, when it is associated with
coeliac disease (CD)) is a common pathological finding in
duodenal biopsies, especially of adults, and is charac-
terised by the increased infiltration of intraepithelial lym-
phocytes (IELs) above 25% of the normal values, based on
counts of 100 epithelial cells, and normal villous architec-
ture [8]. It is becoming increasingly accepted that LEl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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malities observed in CD [9]. In fact, patients with CD have
varying degrees of damage to their small intestinal mu-
cosa, ranging from LE with normal villous structure to
severe villous atrophy (Marsh stage 3). In addition, more
IELs may be the earliest pathological change to occur, fol-
lowing gluten challenge, and may even be the only sign of
gluten sensitivity [10]. Although LE has been considered
by some to be a latent CD, its aetiology cannot be clarified
in about one-third of cases. Indeed, a prospective study of
the aetiology of LE in 100 patients estimated that at least
16% of patients with this condition may actually have CD
[11]. However, a more recent Spanish prospective study of
90 consecutive patients with LE and clinical symptoms of
CD reached a final diagnosis of gluten-sensitive enter-
opathy (GSE), alone or associated with Helicobacter pyl-
ori (HP) infection, in 43% of patients [12]. In addition to
gluten sensitivity, LE may be related to non-steroidal
anti-inflammatory drug (NSAID) intake, intolerance to
non-gluten food protein (for example, cow’s milk, eggs,
peanuts, soya), autoimmune disorders (for example, thy-
roiditis, type I diabetes, rheumatoid arthritis, psoriasis,
multiple sclerosis, systemic lupus erythematosus), in-
flammatory and infectious intestinal tract disorders (for
example, Crohn’s disease, bacterial overgrowth, HP, trop-
ical sprue, and Giardia lamblia, Cryptosporidium and
viral infections), and T-cell intestinal lymphoma [13,14].
Two or more aetiological factors are often associated,
the most frequent of these being NSAIDs, CD and HP
infection [11,12].
Some researchers have reported that patients with LE
(that is, Marsh stage 1) may have the same type of
gastrointestinal and extra-intestinal symptoms as pa-
tients with CD-related villous atrophy [15], and notably
good responses to a gluten-free diet (GFD) have also
been observed in Marsh Stage 1 patients [16–18].
Accordingly, since GSE may be responsible for LE in
16 to 43% of cases and, furthermore, Marsh stage 1 pa-
tients may benefit from a GFD, especially if they have
extraintestinal manifestations [19], the aim of this study
was to analyse the changes in the scores of several
Health-Related Quality of Life (HR-QoL) question-
naires and the Visual Analogue Scales (VAS), before
and after (pre-post) treatment with a GFD for one year,
in two groups of patients recruited by case finding for
CD [4]. One group consisted of subjects with concur-
rent IBS, FMS and LE (Marsh stage 1), and the other of
subjects with IBS and FMS with normal intestinal mu-
cosa (Marsh stage 0).
Methods
As has been reported in two recent articles consecutively
published by our group [4,5], during the six-year period
between 2007 and 2012, we prospectively studied by CDscreening detection a total of 442 consecutive Caucasian
patients who had been referred to the Gastroenterology
Outpatient Clinic of the Central University Hospital of
Asturias, HUCA (Oviedo, Spain) for a variety of chronic
gastrointestinal and systemic symptoms.
Details of subject selection with inclusion and exclusion
criteria, analytical tests performed, HR-QoL question-
naires used, and technical details of collection, staining
and interpretation of gastrointestinal biopsies were exten-
sively described in the aforementioned papers [4,5].
Briefly, 229 out of 442 subjects volunteered to take
part in this study and gave their specific signed informed
consent. Rome III criteria for IBS diagnosis [6] and the
ACR 1990 criteria for FMS classification [7] were ap-
plied to each patient on their first visit. A comprehensive
medical history was taken, patients were given a thor-
ough physical examination, and complete laboratory
haematological and biochemical screening was carried
out. The study was approved by the Research and Ethics
Committee of the HUCA, following the principles of the
modified Declaration of Helsinki.
Cell blood count (CBC) and coagulation studies
were performed with an automated Abbott Hematology
Analyzer (Cell Dyn 3500, Abbott Diagnostics, Santa
Clara, CA, USA) and the Coagulation Analyzer ACL
3000 (Menarini Diagnostics, Florence, Italy), respect-
ively. Biochemical tests were performed with a Hitachi
Modular automated analyzer SXA-PPBD (Roche, Basel,
Switzerland) using enzymatic or kinetic methods to meas-
ure blood urea, glucose, total protein, albumin, C-reactive
protein (CRP), calcium, folate, vitamin B-12, creatinine,
creatine kinase (CK), rheumatoid factor (RF), lipid profile,
liver function, immunoglobulin levels (IgG, IgA and IgM),
iron metabolism, thyroid function, and urine with micro-
scopic examination of the sediment. Anti-nuclear anti-
bodies (ANAs) and anti-thyroid peroxidase (anti-TPO)
antibodies were measured in each participant. In cases
with altered liver function tests (LFTs), anti-mitochondrial
antibodies (AMAs) were assessed by indirect immuno-
fluorescence assay in the Hep-20-10 cell line (Euroimmun,
Lübeck, Germany). Anti-IgA tissue transglutaminase sub-
type 2 (tTG) antibodies were measured with an ELISA
kit from Phadia Diagnostics (Uppsala, Sweden). Major
histocompatibility complex class II (HLA-DQ2) genetic
markers (DQA1*0501 and DQB1*0201 alleles) were de-
termined by a polymerase chain reaction (PCR) with a
ProtransR HLA Celiac Disease Domino System (Pro-
trans, Ketsch, Germany) kit. The HLA-DQ8 haplotype
was identified in a single negative HLA-DQ2 patient
with duodenal villous atrophy.
An upper gastrointestinal endoscopy with at least four
duodenal biopsies was performed following the usual
methods in all patients included in the case finding/screen-
ing. Samples were routinely stained with haematoxylin and
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monoclonal antibodies to verify the presence and count
the number of IELs. These were in turn quantified in
relation to 100 epithelial cells. Samples were studied by
two expert pathologists from the HUCA, and classified
into the following types: Stage 0, normal duodenum;
Stage 1, increased IEL infiltration with a total count
of ≥25%; Stage 2, crypt hyperplasia and presence of dif-
fuse chronic inflammatory infiltration of the lamina
propria; Stage 3, villous atrophy, subdivided into three
categories: (a) mild, (b) moderate and (c) severe, accord-
ing to the histological classification of CD described by
Marsh in 1992 [20] and subsequently modified by
Oberhüber et al. [21].
HP from endoscopic gastric biopsies was systematic-
ally investigated. Antibiotics, proton pump inhibitors
(PPIs), drugs containing bismuth and H2 blockers were
withdrawn during the two preceding weeks. Two antral
biopsies were immediately taken for a rapid urease test
(Pronto Dry Kit, Pentland Medical Ltd, Edinburgh, UK).
The remaining samples were used for histopathological
examination (that is, routine H&E staining, Giemsa
staining and immunohistochemistry using polyclonal
anti-HP antibody) and microbial culture. Positive cases
received triple therapy involving a 14-day treatment with
PPI (40 mg twice a day (bid)), clarithromycin (500 mg
bid), and amoxicillin (1,000 mg bid). After completing
treatment, HP eradication was confirmed four to six
weeks later with a rapid urease breath test [22,23].
In non-responders to usual therapies, doubtful cases
or those suspected of having other associated organic ill-
nesses, a specific breath test was performed to rule out
possible lactose intolerance or a small bowel bacterial
overgrowth. Faecal cultures were grown, when required,
to exclude the possibility of parasitic infections in some
patients. A total colonoscopy was carried out and random
colonic biopsies taken from patients with persistent
diarrhoea to rule out the possible presence of micro-
scopic colitis.
An immunological faecal occult blood test (iFOBT)
was done in patients aged over 50 years and in those
with a positive family history of colon cancer in first-
degree relatives. If the iFOBT was positive the study was
completed with a total colonoscopy.
Tender points (TPs) were identified and their frequency
determined by digital pressure of the 18 anatomical loca-
tions recommended by the ACR 1990 study [7].
To measure physical, mental, psychological, and social
functioning, each patient completed the Spanish versions
of the self-administered Fibromyalgia Impact Question-
naire (FIQ), Health Assessment Questionnaire (HAQ)
and Short Form Health Survey (SF-36) [24–26].
The FIQ comprises a 10-item scale that evaluates the
global impact of the illness on the patient, with a totalscore ranging between 0 and 80 points, derived from
various questions about physical functioning, work status
level, degrees of depression and anxiety, sleep alterations,
severity of pain, stiffness, fatigue and the perception of
wellbeing. Total FIQ scores were divided into three cat-
egories, ranging from 0 to 39 (mild), 40 to 59 (moderate),
and 60 and over (severe) [24].
The HAQ test is a 20-item disability scale of various
4-point ordinal measures of a patient’s difficulty and
need for help and assistive devices in several daily activ-
ities, with higher scores indicating greater impairment
(0 = able to do without any difficulty, 1 = some difficulty,
2 =much difficulty, and 3 = unable to do) [25].
The 36 items of the short form SF-36 questionnaire
cover eight health domains: (1) physical functioning
(PF); (2) role limitations by physical problems (RP); (3)
bodily pain (BP); (4) general health perceptions (GH);
(5) vitality (energy/fatigue) (VT); (6) social functioning
(SF); (7) role limitations due to emotional problems
(RE); (8) mental health/emotional well-being perception
(MH). These eight measures are used to calculate two
weighted aggregate scores: the physical and mental
component summaries (PCS and MCS). Scores may
take values between 0 and 100, higher ones indicating
better health. No threshold values of SF-36 scores have
so far been established that classify the impact of a dis-
ease. For reference, the published values for adults in
the general Spanish population are 73 ± 28 for the PCS
and 74 ± 24 for the MCS [26].
To evaluate the severity of digestive symptoms and the
amount of pain and fatigue experienced by patients, three
types of VAS were used [27–29].
Participants were then assigned to one of two groups:
the first consisted of 104 subjects who fulfilled the
Rome III criteria for IBS diagnosis and the ACR 1990
criteria for FMS classification constituted the IBS plus
FMS group, and the second one of 125 unrelated and
age- and sex-matched subjects, fulfilling the Rome III
criteria for IBS but not those of the ACR 1990 criteria
for FMS, comprised the IBS group. Seven cases with vil-
lous atrophy (7%), 58 with LE (56%) and 39 with a nor-
mal intestinal biopsy (37%) were found in the IBS and
FMS group, while in the group of IBS without FMS we
found 2 subjects with villous atrophy (2%), 20 with LE
(16%) and 105 with a normal biopsy (84%). All patients
with intestinal atrophy were successfully treated with
DSG [5].
The current study was finally limited to 58 cases with
IBS, FMS and LE (Marsh stage 1), and to 39 cases from
the same group with IBS and FMS who had a normal in-
testinal biopsy (Marsh stage 0). Patients in both groups
were treated with a GFD for one year. The diet was
followed as strictly as possible, in order to try to keep
daily gluten consumption to a minimum.
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Continuous parameters were summarised as means and
standard deviations, and medians and ranges. Qualitative
variables were summarised as percentages. Kruskal-Wallis
analysis of variance (ANOVA) and contingency tests were
then undertaken. Normally distributed continuous vari-
ables were analysed with Student’s t test for unpaired sam-
ples, and ANOVA followed by a post hoc Fisher’s test. All
statistical tests were two-sided, with significance con-
cluded for values of P <0.05. Statistical calculations were
performed with SPSS 15.0 (SPSS Inc., Chicago, IL, USA).Table 1 Baseline characteristics of the cohorts
All subjects n = 97 N
(
Demographic characteristics
Females, n (%) 86 (89) 3
Age in years, mean (SD) 50 (8) 4
BMI, kg/m2, mean (SD) 26 (4) 2
Education level
None, n (%) 2 (2) 0
Primary education, n (%) 71 (73) 2
Secondary education, n (%) 22 (23) 1
Higher education, n (%) 3 (3) 0
Employment status
Employed, n (%) 45 (46) 2
Unemployed, n (%) 20 (21) 7
Homemaker, n (%) 17 (17) 8
Retired/pensioner, n (%) 15 (15) 3
First-degree relatives with CD/FMS
Subjects with CD relatives, n (%) 10 (10) 0
Subjects with FMS relatives, n (%) 4 (4) 0
Gastroduodenal histopathological
details
IELs, mean (SD) 18 (3) 1
Helicobacter pylori (+), n (%) 41 (42) 1
HLA haplotype
HLA-DQ2 A1/B1, n (%) 46 (47) 1
HLA-DQ2 (−), n (%) 15 (15) 4
Serum autoantibodies
Anti tTG-2, U/ml, mean (SD) 0.7 (0.6) 0
RF, IU/m, mean (SD) 12.8 (1.7) 1
Anti-TPO (+), U/ml, mean (SD) 30 (111) 2
ANAs (+), n (%) 26 (27) 3
AMAS (+), n (%) 4 (4) 0
Data are expressed as frequency (n) and percentage of the total value (%), or mean
lymphocyte count from 100 epithelial cells; anti-tTG-2, anti-tissue transglutaminase-
complex class II; anti-TPO, anti-thyroid peroxidase antibodies; ANAs, anti-nuclear anResults
Description of the cohorts
Baseline demographic, gender, social, clinical, serological
and genetic characteristics of the IBS/FMS Marsh stage
0 (normal mucosa) and stage 1 (LE) cohorts are shown
in Table 1. Eighty-nine per cent of patients were women.
The mean age of the complete sample was 50 ± 8 years.
There were no significant differences in these numbers
between the cohorts. Patients in both cohorts had a slightly
high body mass index (BMI), indicative of being over-
weight, especially among the constituents of the Marshormal mucosa
Marsh stage 0) n = 39
Lymphocytic enteritis
(Marsh stage 1) n = 58
P
4 (87) 52 (90) 0.959
9 (7) 51 (9) 0.222
5 (3) 28 (5) <0.001
2 (3) 0.658
9 (74) 42 (72) 0.983
0 (26) 12 (21) 0.746
2 (3) 0.658
1 (54) 24 (41) 0.317
(18) 13 (22) 0.782
(20) 9 (15) 0.717
(8) 12 (21) 0.147
10 (17) 0.016
4 (7) 0.248
4 (2) 35 (5) <0.001
7 (43) 24 (41) 0.426
5 (38) 31 (53) 0.214
(10) 11 (19) 0.381
.5 (0.1) 0.9 (0.7) <0.001
2.6 (0.9) 12.9 (2.1) 0.552
0 (30) 51 (140) 0.115
(8) 23 (40) 0.001
4 (7) 0.248
and standard deviation (SD). BMI, body mass index; IELs, intraepithelial
2 antibodies; RF, rheumatoid factor; HLA-DQ2, major histocompatibility
tibodies; AMAs, anti-mitochondrial antibodies.
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in employment status were found.
Ten subjects in the Marsh stage 1 group, but none in
the Marsh stage 0 group, had several coeliac relatives.
Four subjects in the Marsh stage 1 group with no CD
family history, but none in the Marsh stage 0 group, had
relatives with FMS. Approximately equal proportions
(more than 40%) of subjects from the two groups were
positive for HP. No differences between the cohorts were
found with respect to the HLA-DQ2 haplotypes, blood ti-
tres of RF, anti-TPO, and AMAs. However, serum levels of
anti-tGT-2 and ANAs were significantly higher among
Marsh stage 1 patients.Symptoms, associated disorders and prescribed drugs
All patients complained of a combination of the follow-
ing digestive symptoms: heartburn, bloating, diffuse ab-
dominal pain/discomfort, bowel habit alteration, and
constipation and diarrhoea, separately or alternating. The
symptoms first appeared in the patients’ 20s, in the vast
majority of cases. All complained of a number of common
FMS symptoms, including widespread soft-tissue pain, ab-
normal fatigue, sleep disturbances, foggy mind, and so on,
generally starting around two to three decades later than
the onset of the gastrointestinal symptoms. However, no
differences between the two groups were found with re-
spect to gastrointestinal and systemic symptom type or
duration, or in the prevalence of associated diseases.
Patients in both groups took a large number of drugs
of different types. There were no differences between the
groups with respect to drug prescriptions, except that
some Marsh stage 1 patients received opioid patches while
Marsh stage 0 patients did not (Table 2).Comparison of global pre and post outcome measures
The baseline (‘pre’) scores and those after one year of
GFD (‘post’) of both groups for the TPs, FIQ, HAQ, VAS
and SF-36 questionnaires are illustrated as box-and-
whisker plots, which show the mean (50th percentile)
and range (10th, 25th, 75th and 90th percentiles) of each
outcome (Figure 1).
A very significant decrease in the mean score of TPs
was observed in the Marsh stage 1 group (pre = 16.9 vs.
post = 12.2, P <0.0001). In contrast, no significant changes
were found in the Marsh stage 0 group (pre = 14.8 vs.
post = 14.3).
A very significant 20-point drop in the FIQ mean score
was observed in the Marsh stage 1 group (pre = 70.1 vs.
post = 50.1, P <0.0001). There was also a slight drop in
the FIQ score in the Marsh stage 0 group (pre = 63.4 vs.
post = 61.1, P <0.05).
A modest but significant decrease in the HAQ score
was observed in the Marsh stage 1 group (pre = 1.6 vs.post = 1.1, P <0.05), but not in the Marsh stage 0 group
(pre = 1.4 vs. post = 1.4).
A highly significant decrease in the VAS digestive
symptom score was observed in the Marsh stage 1 group
(pre = 47.5 vs. post = 33.2, P <0.0001), whereas the change
in the Marsh stage 0 group (pre = 45.9 vs. post = 44.0) was
not significant.
There was a significant decrease in the VAS pain score
in the Marsh stage 1 group (pre = 8.6 vs. post = 6.2,
P <0.0001), but not in the Marsh stage 0 group (pre =
7.0 vs. post = 6.8).
There was a significant decrease in the VAS fatigue
score in the Marsh stage 1 group (pre = 8.6 vs. post = 6.4,
P <0.0001), but no significant change in the Marsh stage
0 group (pre = 7.1 vs. post = 6.8).
There was a significant increase in the SF-36 PCS in
the Marsh stage 1 group (pre = 28.6 vs. post = 36.5,
P <0.0001), but not in the Marsh stage 0 group (pre = 30.0
vs. post = 31.0).
A very significant increase in the SF-36 MCS was ob-
served in the Marsh stage 1 group (pre = 25.5 vs. post =
32.1, P <0.0001), whereas there was no significant change
in the Marsh stage 0 group (pre = 35.5 vs. post = 36.5).
Discussion
The most remarkable finding in the present study was
the partial but statistically significant improvement in all
measured parameters after one year of continuous treat-
ment with a GFD in patients of the IBS/FMS/LE (that is,
Marsh stage 1 in terms of CD) group, compared with
the modest or negligible improvements found in the
group of patients with IBS/FMS and normal intestinal
mucosa (that is, Marsh stage 0 in terms of CD).
Overall, after one year of sustained GFD a significant
improvement (26 to 30%) in all outcome measures was
achieved in the IBS/FMS/LE (Marsh stage 1) group com-
pared with 3 to 4% in the IBS/FMS (Marsh stage 0)
group. Specifically, the percentage differences in each
parameter between Marsh stage 1 and stage 0 patients
were: TPs, 28.0 vs. 3.2%; FIQ, 27.7 vs. 3.6%; HAQ, 28.4
vs. 3.4%; VAS digestive, 29.7 vs. 4.1%; VAS pain, 27.4 vs.
3.5%; VAS fatigue, 26.2 vs. 3.4%; SF-36 PCS, 27.3 vs.
3.8%; and SF-36 MCS, 27.2 vs. 3.7%. The improvements
in the physical and mental components of the SF-36
were also significant, even though they were only 50%
and 43%, respectively, of the estimated general Spanish
population mean [26].
The small improvement in the scores of the IBS/FMS/
Marsh stage 0 group did not have any clinical conse-
quences. However, the larger improvement in scores ob-
tained in the Marsh stage 1 group, though not completely
resolving the symptoms of any case, did produce a reduc-
tion in the severity of the ailments, and ultimately a
substantially favourable effect on patients’ HR-QoL. For
Table 2 Symptoms, associated disorders and prescribed drugs
Symptoms, n (%) All cases n = 97 Normal mucosa
(Marsh stage 0) n = 39
Lymphocytic enteritis
(Marsh stage 1) n = 58
P
Widespread soft-tissue pain 97 (100) 39 (100) 58 (100) 1.000
Digestive complaints† 97 (100) 39 (100) 58 (100) 1.000
Fatigue 88 (91) 35 (90) 53 (91) 0.932
Sleep disturbances 81 (83) 29 (74) 52 (89) 0.087
Anxiety/depression 64 (66) 22 (56) 42 (72) 0.158
Skin problems‡ 48 (49) 20 (51) 28 (48) 0.934
Foggy mind 34 (35) 14 (36) 20 (34) 0.941
Urinary urgency 28 (29) 10 (26) 18 (31) 0.729
Balance problems/dizziness 27 (28) 10 (26) 17 (29) 0.869
Chronic headaches⊥ 26 (27) 5 (13) 21 (36) 0.021
Joint stiffness 25 (26) 9 (23) 16 (28) 0.794
Paraesthesias 23 (24) 9 (23) 14 (24) 0.902
Associated disorders, n (%)
Osteoporosis 12 (12) 2 (5) 10 (17) 0.144
TMJ disorder 11 (11) 5 (13) 6 (10) 0.959
Restless legs 11 (11) 3 (8) 8 (14) 0.547
Symptom duration, years, mean (SD)
Gastrointestinal symptoms 29 (6) 29 (5) 29 (8) 0.029
Extraintestinal symptoms 9 (2) 9 (2) 9 (2) 0.501
Prescribed drugs, n (%)
Analgesics* 79 (81) 34 (87) 45 (78) 0.344
Omeprazole 76 (78) 29 (74) 47 (81) 0.595
Antidepressants⊥ 65 (67) 25 (64) 40 (69) 0.780
Pregabalin 55 (57) 19 (49) 36 (62) 0.275
Benzodiazepines/hypnotics 55 (57) 20 (51) 35 (60) 0.500
Antispasmodics/Antidiarrhoeals† 37 (38) 17 (38) 33 (57) 0.281
Laxatives 13 (13) 10 (26) 27 (47) 0.062
†Digestive complaints consisted of a combination of at least two of the following symptoms: bloating, heartburn, epigastric pain, diffuse abdominal pain,
constipation and diarrhoea (separately or alternating); ‡skin problems included: itchy/dry/burning skin, dermographism, chronic urticaria, and one case of
herpetiformis dermatitis; ⊥chronic headaches encompassed: migraines, muscle tension and combination headaches; *analgesics were usually used on an irregular
basis (on demand), and generally consisted of non-steroidal anti-inflammatory drugs, paracetamol, tramadol, metamizol and codeine; ⊥antidepressants: tricyclic
antidepressants, selective serotonin reuptake inhibitors, other antidepressants; †antispasmodics: mebeverine and/or otilonium bromide; †antidiarrhoeals:
loperamide, diphenoxylate/atropine. TMJ: temporomandibular joint.
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involved a partial but appreciable improvement in the se-
verity of FMS, from ‘severe’ to ‘moderate’. However, the
apparently modest drop in the HAQ score meant that al-
though patients continued to have difficulties performing
normal daily activities, doing so involved less drudgery.
The VAS for digestive symptoms changed from ‘severe’ to
‘moderate’, the VAS for pain changed from ‘very poor’ to
‘moderately tolerable’, and a similar result was obtained
for the intensity of patients’ perceived exertion.
Recent findings have demonstrated that the spectrum
of gluten-related disorders includes, along with CD, a
new syndrome, defined as non-coeliac gluten sensitivity
(NCGS) by the two Consensus Conferences held inLondon (2011) [30] and Munich (2012) [31]. The pa-
tients described herein share the typical clinical picture
of this new syndrome, which is characterised by IBS-like
gastrointestinal symptoms and a range of extraintestinal
signs that also include joint/muscle pain resembling
FMS. The majority of the other symptoms, reported in
Table 2, are consistent with the clinical characteristics of
NCGS: digestive complaints, fatigue, sleep disturbances,
anxiety, depression, skin problems, cognitive dysfunction
(‘foggy mind’), headache and paraesthesias. As is gener-
ally acknowledged, the diagnosis of NCGS implies the
exclusion of a diagnosis of CD on the basis of negative
coeliac serology (tTG and EmA) and the absence of vil-
lous atrophy in the intestinal biopsy. The histology of
Figure 1 Comparative results of clinical evaluation tests in Marsh stage 1 vs. stage 0 patients, at baseline and after one year of GFD.
FIQ, Fibromyalgia Impact Questionnaire; GFD, gluten-free diet; HAQ, Health Assessment Questionnaire; Marsh-1, lymphocytic enteritis; Marsh-0,
normal mucosa; SF-36, Short Form Health Survey; VAS, Visual Analogue Scale. In the box-and-whisker plots, the box is delimited by the 25th and
75th percentiles, the horizontal line within the box marks the 50th percentile (median), and the whiskers indicate the 10th and 90th percentiles.
***P <0.0001; **P < 0.001; *P <0.05.
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about 60% of cases and by LE (Marsh 1) in the remaining
40%. This concept is very important and we want to
clearly underline that an isolated LE is never an expression
of potential CD.
It has been shown that first-generation antigliadin anti-
bodies (AGAs) are the only serological markers found in a
significant proportion of patients with NCGS. Several
authors have shown that these antibodies are present in
a significant proportion (around 50%) of patients with
NCGS [32–34]. We did not measure the AGAs in our pa-
tients because our study population comprises only adults,
whose sensitivity and specificity are low (around 50% in
both cases), making the routine use of AGAs of no diag-
nostic use in either patients with LE or cases of NCGS.
AGAs have been shown to be of use only in chil-
dren under three years of age and have been largely
superseded by anti-peptide antibodies of deamidated
gliadin (anti-DGP), which are also of use in children,
but not in adults.CD is a multisystemic autoimmune disorder related to
a permanent intolerance to gluten, a protein found in
bread, pasta, cookies, pizza crust and many other foods
containing wheat, barley, rye and oats. It affects 1 to 2%
of the population, predominantly women, worldwide.
People with the disorder are generally carriers of one of
the two HLA-II genotypes, DQ2 and DQ8. In these sub-
jects, gliadin peptides trigger an aberrant immune re-
sponse, resulting in the production of tTG autoantibodies
and an immune-mediated chronic inflammation of the
small bowel mucosa that is associated with an increase in
the number of lymphocytes in the epithelium, and facili-
tates the appearance of elongated hyperplastic crypts, cu-
boidal enterocytes with damaged brush borders, a dense
infiltration of the lamina propria by lymphocytes and
plasma cells, a high IEL count on the surface epithelium,
and ultimately, villous atrophy featuring shortened or to-
tally absent villi [20,21]. These histological abnormalities
can develop gradually in subsequent phases, and although
the onset of symptoms is usually characterised by a time
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can appear at any age during adulthood and at any
histopathological stage, with gastrointestinal and/or extra-
intestinal systemic manifestations. However, some coeliac
subjects may remain oligosymptomatic or asymptomatic
throughout their lifetime. Notably, a GFD brings about
complete clinical remission and full recovery of the intes-
tinal damage in the vast majority of CD patients [35].
The diagnosis of CD has conventionally been based on
the histopathological changes of the proximal small bowel
mucosa, mucosal atrophy being considered a fundamental
change with which CD may be diagnosed with certainty,
and on this basis, a GFD prescribed [35,36]. The strict ap-
plication of this criterion would prevent the inappropriate
prescription of GFD, a measure which is potentially ex-
pensive, difficult to maintain and socially restrictive [11].
However, CD has a wide spectrum of histological abnor-
malities, ranging from LE with normal villous architecture
to flattened mucosa. Interestingly, these morphological
changes occur independently of the patients’ symptoms
and the interpretation of the clinical significance of LE re-
mains controversial [37,38].
Some authors believe that since mucosal damage can
develop gradually, and that some LE patients can present
clinical symptoms of CD before major histological ab-
normalities appear, it might be unethical not to recom-
mend a GFD to LE patients whose clinical data suggest
CD [16–19]. According to this argument, the recogni-
tion of CD at this early stage would be important and
very useful because these patients may develop symp-
toms and complications that could be improved or pre-
vented by a GFD [39].
Identifying CD in patients with LE is a challenge for
clinicians. It is best done by carrying out several specific
serological and genetic diagnostic tests on a routine clin-
ical basis to obtain a differential diagnosis of the various
clinically suspicious entities, such as functional dyspepsia
and IBS. This enables the identification of gluten-related
histological changes, which can inform the decision to
prescribe a GFD, and the assessment of the clinical/histo-
logical improvement produced by the diet [40,41].
Further evidence is required that the diagnosis of CD
should always involve testing for class 2 HLA genotypes
encoding DQ2 or DQ8, and tTG and⁄or anti-endomysial
antibodies (EMAs) in the presence of normal IgA levels
[11]. A retrospective comparative study of 124 patients
with LE and 454 CD patients found that the LE cohort
differed significantly in terms of the HLA type (51% of LE
patients were negative for DQ2 or DQ8, whereas only 2%
CD patients had neither DQ2 nor DQ8), in tGT and EMA
serum antibodies (12% vs. 87% and 0% vs. 87%, respect-
ively), and with respect to several clinical features (for ex-
ample, LE was less frequently associated with anaemia,
malaise or skin disorders, or with a positive family historyof CD) [42]. However, patients with LE who are on the
CD spectrum generally have negative coeliac serology
(measured by tGT and EMA), and their positivity is
strongly correlated with the severity of mucosal damage
[43]. On the other hand, although the HLA DQ2 or
DQ8 phenotypes are closely associated with CD (occur-
ring in up to 98% of cases), they are not specific enough
to establish a diagnosis of CD, since they are also found
in over 25% of the general population. In any case, the
absence of the genes predisposing for CD (the HLA-DQ2
and/or HLA-DQ8 haplotypes) makes CD very unlikely,
because they have a high negative predictive value for this
disease [35,44].
The presence of intestinal deposits specific for tTG2
IgA is a more sensitive marker of CD than serum tTGA,
but is less specific, since more than 10% of controls have
positive deposits. The technique for measuring it is not
currently available in most clinical laboratories, and its
clinical utility is not well established [45,46].
In contrast to duodenal TG2 IgA deposits, tTG anti-
bodies in the supernatant of cultured duodenal biopsies
and duodenal aspirates show greater specificity for the
diagnosis of GSE, and thus, when positive, are of great
value in the differential diagnosis of LE due to GSE from
other forms of LE. Again, the clinical utility of this tech-
nique is not yet well established [47].
The immunophenotyping pattern of IELs in CD shows
a characteristic feature of elevated CD3+ IELs (αβ and
γδ TcR) and decreased CD3- IELs [48,49]. The increase
in γδ- IELs is a pathognomonic (never described in other
gastrointestinal disorders) and irreversible feature of CD
patients, even in those who are GFD-compliant. Other cy-
tometric abnormalities described in CD patients are the
decreases in CD3−, CD103+, CD7+ and CD45+ IELs [19].
Nevertheless, this promising and sophisticated technique
is not available in most clinical laboratories, so its true
value has yet to be demonstrated.
A gluten challenge can cause further mucosal deterior-
ation in patients with potential CD in whom initial small
intestinal biopsies reveal only minor abnormalities. This
was demonstrated by a prospective study of 38 patients
with Marsh stage 1 lesions who underwent a gluten chal-
lenge (30 g per day of gluten added to a normal diet for
eight weeks) [50]. This worsened the histological lesions
in 12 patients (32%), while lesions remained unchanged in
the other 26 patients. Additionally, the 12 patients who
experienced worsening of their duodenal lesions with glu-
ten provocation subsequently experienced symptoms of
relief when placed on a GFD. In light of these results it
was proposed that a gluten challenge could be useful for
identifying gluten-sensitive patients. However, this strategy
is time-consuming, expensive and aggressive, because it
requires repeating small intestinal biopsies, so it is not rec-
ommended in clinical practice.
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on a clinical and histological response to a GFD in indi-
viduals with CD-associated symptoms, positive serology
(tGT and EmA), and compatible HLA coeliac predispos-
ition genes. A drawback of this strategy is that it is time-
consuming and requires good adherence to the follow-up
by patients and physicians. Nevertheless, it might be a rea-
sonable alternative in cases in which the doctor lacks suffi-
cient means to ensure an accurate diagnosis, and in which
the patient accepts testing with a GFD [51].
While there is currently no consensus among gastroen-
terologists about whether to treat all Marsh stage 1 pa-
tients with a GFD, there are a few published clinical trials
supporting the use of the GFD in selected patients with
LE [16–18]. For example, in 2003 Tursi and Brandimarte
[16] assessed the benefit of a GFD in 35 young Italian pa-
tients with small bowel mucosal abnormalities (lymphocy-
tosis type) with or without crypt hyperplasia (Marsh
stages 1 to 2) and various symptoms suggestive of gluten
sensitivity (for example, diarrhoea, abdominal pain, flatu-
lence, weight loss, chronic fatigue, and so on). Remark-
ably, a dramatic clinical improvement in all symptoms
was observed, although not always accompanied by an im-
provement in the histological lesions, in almost all patients
after 8 to 12 months on a sustained GFD. This finding, in
the opinion of the study’s authors, supports the suspicion
that these patients were sensitive to gluten, and would jus-
tify starting them on a GFD. This study also found that
IgG AGA, IgA EMA and IgA tGT antibodies, with 5%, 8%
and 17% positivity, respectively, were poor indicators of
CD in these ‘borderline’ LE cases. The reason for the
failure may be the low prevalence of these antibodies in
patients with mild histological lesions but without vil-
lous atrophy [43].
A subsequent prospective, randomised, controlled clin-
ical trial in 23 EMA-positive patients with LE inflamma-
tion (Marsh stage 1/2) was performed by Kurppa et al. in
Finland [17]. Patients were randomised either to con-
tinue on a normal gluten-containing diet or to adhere
to a strict GFD. In the gluten-containing diet group the
small bowel mucosal villous architecture deteriorated in
all subjects, and symptoms and high serum antibody
levels did not appreciably change. In contrast, the
symptoms of subjects in the GFD group were alleviated,
their antibody titres decreased and their mucosal in-
flammation diminished. When the trial was completed,
all participants chose to continue on a life-long GFD.
One year later, Kurppa et al. reported the results of an-
other prospective trial with GFD in 73 EMA-positive
adults, which showed Marsh stages 1/2 and 3 changes
in duodenal biopsies. They found that patients who
were Marsh stage 1/2 at baseline had more digestive
symptoms and lower bone density than those with atro-
phy, and that the symptoms and bone mineralisation ofmost of them improved when they were placed on a
GFD [18].
To our knowledge, there are no published therapeutic
trials apart from the present one that examine the effect
of a GFD in patients with concomitant LE, IBS and
FMS, so comparisons with other studies are not possible.
Nevertheless, we believe it is important to point out that
our patients were suffering from severe FMS, a very nega-
tive intercurrent disease, because it is widely accepted that
this disorder is highly refractory to all available therapies.
In this regard, a classic study of patients with established
FMS seen at several American rheumatological centres
showed that they had markedly abnormal scores for pain,
functional disability, fatigue, sleep disturbance and psy-
chological status, and that these values did not change
substantially over a prolonged follow-up period. Values at
the first assessment predicted final values; half the patients
were dissatisfied with their health, and most of them rated
their health as fair or poor [52].
An example of the difficulty of controlling the FMS as-
sociated with CD is provided by a recent study performed
in Italy, which found 13 patients with FMS (11.4%) among
114 CD subjects. Based on the subjective testimony of
these patients, their widespread pain symptomatology
began several years before the diagnosis of CD and their
FMS symptoms were minimally improved by, or did not
benefit at all, from the GFD [53].
Nevertheless, a more recent trial by our group in seven
screening-detected CD adult females, also categorised as
severe IBS and FMS patients, demonstrated that the
TPs, FIQ, HAQ, VAS scales, and SF-36 PCS and MCS
scores were significantly improved by 50 to 60%, accom-
panied by a decrease in tTG-2 to normal values, after
one year of the GFD. These results suggest that a signifi-
cant positive outcome was obtained with the GFD, al-
though the symptoms did not completely disappear in
any of the cases [5].
Conclusions
In summary, although there is currently little scientific
evidence, and we are not able to draw definite conclu-
sions about the effectiveness of the GFD in FMS
patients, it seems reasonable to infer that GFD is not
appropriate for patients with a normal intestinal biopsy
(Marsh stage 0), and that more accurate, randomised,
double-blind, placebo-controlled studies of greater stat-
istical power are required to assess this recommenda-
tion before applying it widely to patients with FMS and
LE (Marsh stage 1).
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